Granix by Teva Pharmaceuticals, Inc
Teva bolsters its biosimilar business through $160m Celltrion deal
Granix
In Focus: Making the case for biosimilars - MM+M - Medical Marketing and Media
Granix Indication Expanded to Include Pediatric Patients - MPR
New Drug Product: GRANIX - MPR
FDA approves new indication, vial presentation for Teva's Granix | Drug Store News
Resources & Support from Teva CORE | GRANIX
Teva Pharmaceuticals - pdf download
TEVA PHARMACEUTICALS USA, INC: Teva Announces Updated Indication and Vial Presentation for GRANIX® (tbo-filgrastim) Injection in United States | American Pharmacy News
Granix® Hematopoietic Agent TBO-Filgrastim, Preservative Free 480 mcg / 0.8 mL Subcutaneous Injection Prefilled Syringe 5 Syringes
63459091236 - Henry Schein Medical
15_03.jpg
Teva Is a Hold
NDC 63459-910 Granix Tbo-filgrastim
GRANIX (TBO-FILGRASTIM) INJECTION Trademark of TEVA Pharmaceutical Industries Limited Serial Number: 86040042 :: Trademarkia Trademarks
These highlights do not include all the information needed to use GRANIX safely and effectively. See full prescribing information for GRANIX.GRANIX® (tbo-filgrastim) injection, for subcutaneous use Initial U.S. Approval: 2012
US Pharmacist January 2016
GRANIX - TEVA Pharmaceutical Industries Limited Trademark Registration
Teva bolsters its biosimilar business through $160m Celltrion deal
GRANIX Dosage & Rx Info | Uses, Side Effects
Teva - Contract Pharma
Market Share by Filgrastim Brand (As a Percentage of Sales Before Rebates) | Download Scientific Diagram
A Look at Teva's Dominance in the Biosimilar Space
These highlights do not include all the information needed to use GRANIX safely and effectively. See full prescribing information for GRANIX.GRANIX® (tbo-filgrastim) injection, for subcutaneous use Initial U.S. Approval: 2012
Teva's Granix Gets FDA Approval for Expanded Indication
